Similar articles

• Protocol core biopsy as intermediate efficacy end-point in chronic kidney allograft rejection.

  Yilmaz S, Taskinen E, Häyry P, Isoniemi H. Yilmaz S, et al. Transplant Proc. 1996 Feb;28(1):491-3. Transplant Proc. 1996. PMID: 8644324 Review. No abstract available.
• Morphological criteria of chronic rejection: differential diagnosis, including cyclosporine nephropathy.

  Mihatsch MJ, Ryffel B, Gudat F. Mihatsch MJ, et al. Transplant Proc. 1993 Apr;25(2):2031-7. Transplant Proc. 1993. PMID: 8470264 No abstract available.
• Long-term effects of chronic cyclosporine nephropathy on outcome of renal allografts.

  Takeda A, Morozumi K, Haba T, Katayama A, Tominaga Y, Uchida K. Takeda A, et al. Transplant Proc. 2001 Nov-Dec;33(7-8):3379-80. doi: 10.1016/s0041-1345(01)02455-1. Transplant Proc. 2001. PMID: 11750445 No abstract available.
• Immunologic and nonimmunologic contributors to glomerular segmental sclerosis in renal transplantation.

  Jeong HJ, Kim YS, Oh CK, Park K, Choi IJ. Jeong HJ, et al. Transplant Proc. 1996 Jun;28(3):1224-5. Transplant Proc. 1996. PMID: 8658635 No abstract available.
• The differential diagnosis between rejection and cyclosporine toxicity.

  Mihatsch MJ, Ryffel B, Gudat F. Mihatsch MJ, et al. Kidney Int Suppl. 1995 Dec;52:S63-9. Kidney Int Suppl. 1995. PMID: 8587287 Review. No abstract available.